Ev
Not verified

Evommune, Inc.

What we write about

BiotechnologyHealthIndustriaMedicine - variousPharmaceuticals
09/11/2026
WEB AND SOCIAL NETWORK
Eventi
Fairs
Biotechnology
Health
Pharmaceuticals
Medicine - various
Evommune to Present at Upcoming Investor Conferences
1.00
05/11/2026
WEB AND SOCIAL NETWORK
Biotechnology
Health
Pharmaceuticals
Medicine - various
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
1.00
04/11/2026
Labour market
Finance
Biotechnology
Pharmaceuticals
Health
Medicine - various
Evommune Announces $30 Million Private Placement
1.00
04/11/2026
Labour market
Finance
Biotechnology
Pharmaceuticals
Health
Medicine - various
Evommune Announces $30 Million Private Placement
1.00
04/11/2026
Labour market
Health
Sanità
Medicine - various
Pharmaceuticals
Biotechnology
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
1.00
08/09/2026
Industria
Health
Sanità
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
1.00
06/08/2026
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
1.00
30/07/2026
Industria
Biotechnology
Health
Pharmaceuticals
Medicine - various
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
1.00

Contact details

Social Media

Followers
0
Compatibility
0